903 related articles for article (PubMed ID: 33336648)
1. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
2. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
Kuchay MS; Misra A
Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
[TBL] [Abstract][Full Text] [Related]
3. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
5. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
Belfort-DeAguiar R; Lomonaco R; Cusi K
J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease.
Isaacs S
Endocrinol Metab Clin North Am; 2023 Mar; 52(1):149-164. PubMed ID: 36754491
[TBL] [Abstract][Full Text] [Related]
7. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
Basu R; Noureddin M; Clark JM
Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
Cariou B; Byrne CD; Loomba R; Sanyal AJ
Diabetes Obes Metab; 2021 May; 23(5):1069-1083. PubMed ID: 33464677
[TBL] [Abstract][Full Text] [Related]
13. Management of nonalcoholic fatty liver disease in the Middle East.
Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
15. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
Golabi P; Owrangi S; Younossi ZM
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review.
Lu R; Liu Y; Hong T
Diabetes Obes Metab; 2023 Apr; 25 Suppl 1():13-26. PubMed ID: 36775938
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
Theel W; Boxma-de Klerk BM; Dirksmeier-Harinck F; van Rossum EFC; Kanhai DA; Apers J; van Dalen BM; de Knegt RJ; Holleboom AG; Tushuizen ME; Grobbee DE; Wiebolt J; Castro Cabezas M
Obes Rev; 2022 Aug; 23(8):e13481. PubMed ID: 35692179
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective.
Dokmak A; Lizaola-Mayo B; Trivedi HD
Am J Med; 2021 Jan; 134(1):23-29. PubMed ID: 32931760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
